PFO
CYTK icon

Pathstone Family Office’s Cytokinetics CYTK Stock Holding History

Pathstone Family Office’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-110
Closed -$1K – 772
2020
Q1 		$1K Buy
+110
New +$1.4K ﹤0.01% 713

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Pathstone Family Office's CYTK Position: Q2 2020 in Review

Pathstone Family Office sold out of Cytokinetics (CYTK) in Q2 2020, closing a stake of 110 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in CYTK in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 158 funds tracked by Wall St. Rank hold CYTK as of Q2 2020.

  • Pathstone Family Office reported no remaining Cytokinetics position as of Q2 2020 after selling out during the quarter.
  • Pathstone Family Office sold 110 Cytokinetics shares in Q2 2020, an estimated $1K.
  • Pathstone Family Office first reported a position in Cytokinetics in Q1 2020 and held it in 1 quarter.
  • Pathstone Family Office's Cytokinetics position peaked at $1K in Q1 2020.
  • 158 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.